Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13660347 | 0.78 | MEN1 (0.45) | LMNAL3MBTL1ALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL10971819 | 0.77 | GAA (0.47) | LMNAL3MBTL1ALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL1457249 | 0.77 | ALDH1A1 (0.37) | ALDH1A1 | |
| SCHEMBL14008189 | 0.76 | THRB (0.44) | LMNAL3MBTL1ALDH1A1POLBMEN1 | |
| SCHEMBL14008192 | 0.74 | LMNA (0.33) | LMNA | |
| Ethylene SCHEMBL9816770 | 0.72 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL16316350 | 0.71 | POLB (0.40) | ALDH1A1POLBMEN1KMT2A | |
| SCHEMBL13660343 | 0.71 | ALDH1A1 (0.45) | LMNAALDH1A1POLBSMN1; SMN2MEN1 | |
| SCHEMBL10072302 | 0.70 | TSHR (0.41) | ALDH1A1MEN1KMT2A | |
| SCHEMBL13660344 | 0.70 | MEN1 (0.58) | LMNAALDH1A1POLBSMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110071319-A1 | METHOD FOR PREPARING HALOGENATED ORGANOPHOSPHINES | CYTEC CANADA INC. (CA) | 2011-03-24 | — | — | US | disclosed |
| EP-2297171-A2 | METHOD FOR PREPARING HALOGENATED ORGANOPHOSPHINES | Cytec Canada Inc. (CA) | 2011-03-23 | — | — | EP | disclosed |
| WO-2009147495-A2 | METHOD FOR PREPARING HALOGENATED ORGANOPHOSPHINES | CYTEC CANADA INC. (CA) | 2009-12-10 | — | — | WO | disclosed |
| US-20080182202-A1 | Planographic printing plate material and resin used therein | KONICA MINOLTA MEDICAL & GRAPHIC, INC. (JP) | 2008-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071319-A1 | METHOD FOR PREPARING HALOGENATED ORGANOPHOSPHINES | NR1H3, NR1H2, LPAR3 | LMNA 3968/4885L3MBTL1 3081/4885ALDH1A1 3748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.